MX2011001093A - Glutaminil ciclasa como un indicador para el diagnostico / pronostico de enfermedades neurodegenerativas. - Google Patents
Glutaminil ciclasa como un indicador para el diagnostico / pronostico de enfermedades neurodegenerativas.Info
- Publication number
- MX2011001093A MX2011001093A MX2011001093A MX2011001093A MX2011001093A MX 2011001093 A MX2011001093 A MX 2011001093A MX 2011001093 A MX2011001093 A MX 2011001093A MX 2011001093 A MX2011001093 A MX 2011001093A MX 2011001093 A MX2011001093 A MX 2011001093A
- Authority
- MX
- Mexico
- Prior art keywords
- amount
- further characterized
- biological sample
- detected
- normal control
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 40
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 title claims abstract description 30
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 title claims abstract description 30
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 26
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 97
- 201000010374 Down Syndrome Diseases 0.000 claims abstract description 15
- 206010044688 Trisomy 21 Diseases 0.000 claims abstract description 4
- 238000002405 diagnostic procedure Methods 0.000 claims abstract 2
- 239000012472 biological sample Substances 0.000 claims description 70
- 108010029485 Protein Isoforms Proteins 0.000 claims description 43
- 102000001708 Protein Isoforms Human genes 0.000 claims description 43
- 238000004458 analytical method Methods 0.000 claims description 31
- 238000000338 in vitro Methods 0.000 claims description 27
- 239000000523 sample Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108010012236 Chemokines Proteins 0.000 claims description 21
- 102000019034 Chemokines Human genes 0.000 claims description 21
- 230000001149 cognitive effect Effects 0.000 claims description 18
- 210000002381 plasma Anatomy 0.000 claims description 15
- 230000007812 deficiency Effects 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 13
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 238000003127 radioimmunoassay Methods 0.000 claims description 11
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 10
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 10
- 238000004949 mass spectrometry Methods 0.000 claims description 10
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 9
- 101000585315 Homo sapiens Glutaminyl-peptide cyclotransferase Proteins 0.000 claims description 9
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 238000004817 gas chromatography Methods 0.000 claims description 8
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 230000000951 immunodiffusion Effects 0.000 claims description 5
- 238000010166 immunofluorescence Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000000090 biomarker Substances 0.000 claims description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 230000004952 protein activity Effects 0.000 claims description 4
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 3
- 102100021933 C-C motif chemokine 25 Human genes 0.000 claims description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 3
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 3
- 101150011672 CCL9 gene Proteins 0.000 claims description 3
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 claims description 3
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 claims description 3
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims description 3
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 claims description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 3
- 101710095468 Cyclase Proteins 0.000 claims description 2
- 102100023703 C-C motif chemokine 15 Human genes 0.000 claims 2
- 102100023700 C-C motif chemokine 16 Human genes 0.000 claims 2
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 claims 2
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 abstract description 7
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 206010012289 Dementia Diseases 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 208000037259 Amyloid Plaque Diseases 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000006999 cognitive decline Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000001423 neocortical effect Effects 0.000 description 4
- 229940043131 pyroglutamate Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 240000006432 Carica papaya Species 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102100029846 Glutaminyl-peptide cyclotransferase Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 210000000974 brodmann area Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- -1 for example Proteins 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- 108010025516 AbetapE3 peptide Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 2
- 108090000915 Aminopeptidases Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710090339 Glutaminyl-peptide cyclotransferase-like protein Proteins 0.000 description 2
- 102100029865 Glutaminyl-peptide cyclotransferase-like protein Human genes 0.000 description 2
- 101001129465 Homo sapiens Pyroglutamyl-peptidase 1 Proteins 0.000 description 2
- 101100086105 Homo sapiens QPCTL gene Proteins 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 2
- 102100031108 Pyroglutamyl-peptidase 1 Human genes 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004460 liquid liquid chromatography Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101000585397 Homo sapiens Glutaminyl-peptide cyclotransferase-like protein Proteins 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000012412 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 1
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 238000012733 comparative method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000011437 continuous method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000046768 human CCL2 Human genes 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91045—Acyltransferases (2.3)
- G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
- G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8515408P | 2008-07-31 | 2008-07-31 | |
| PCT/EP2009/059951 WO2010012828A2 (en) | 2008-07-31 | 2009-07-31 | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011001093A true MX2011001093A (es) | 2011-03-15 |
Family
ID=41256108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011001093A MX2011001093A (es) | 2008-07-31 | 2009-07-31 | Glutaminil ciclasa como un indicador para el diagnostico / pronostico de enfermedades neurodegenerativas. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100028918A1 (OSRAM) |
| EP (1) | EP2329274B1 (OSRAM) |
| JP (1) | JP5677297B2 (OSRAM) |
| KR (1) | KR101682728B1 (OSRAM) |
| CN (2) | CN103983787A (OSRAM) |
| AU (1) | AU2009275869B2 (OSRAM) |
| BR (1) | BRPI0916601B1 (OSRAM) |
| CA (1) | CA2731933A1 (OSRAM) |
| EA (1) | EA025107B1 (OSRAM) |
| IL (1) | IL210266A (OSRAM) |
| MX (1) | MX2011001093A (OSRAM) |
| NZ (1) | NZ590658A (OSRAM) |
| SG (1) | SG193148A1 (OSRAM) |
| WO (1) | WO2010012828A2 (OSRAM) |
| ZA (1) | ZA201100177B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013519891A (ja) * | 2010-02-18 | 2013-05-30 | プロビオドルグ エージー | ピログルタミン酸修飾ｍｃｐ−１を決定することにより炎症性疾患を診断する方法及びグルタミニルシクラーゼの阻害剤のスクリーニング方法 |
| JP2014515364A (ja) | 2011-05-27 | 2014-06-30 | プロビオドルグ エージー | 放射能標識グルタミニルシクラーゼ阻害剤 |
| US20170363645A1 (en) | 2014-12-19 | 2017-12-21 | Probiodrug Ag | Novel Method for the Detection of pGlu-Abeta Peptides |
| CN104946680A (zh) * | 2015-06-11 | 2015-09-30 | 深圳大学 | 用于表达qc的重组载体及其制备方法、引物、基因工程菌 |
| KR102362919B1 (ko) * | 2016-07-08 | 2022-02-16 | 아지노모토 가부시키가이샤 | 경도 인지 장해 또는 알츠하이머형 인지증의 평가 방법 |
| KR102858457B1 (ko) * | 2023-06-07 | 2025-09-11 | 계명대학교 산학협력단 | Ccl8 단백질 또는 이를 코딩하는 유전자를 유효성분으로 포함하는 퇴행성 뇌질환 진단용 바이오마커 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4374316B2 (ja) * | 1993-01-25 | 2009-12-02 | 武田薬品工業株式会社 | β−アミロイドまたはその誘導体に対する抗体およびその用途 |
| JP3590468B2 (ja) * | 1996-01-22 | 2004-11-17 | 財団法人 東京都医学研究機構 | アルツハイマー病診断薬 |
| EP1523499A2 (en) * | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| MXPA05011861A (es) * | 2003-05-05 | 2006-02-17 | Probiodrug Ag | Uso de efectores de ciclasas de glutamato y glutaminil. |
| CA2542419C (en) * | 2003-10-15 | 2013-06-04 | Probiodrug Ag | Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia |
| US20060094064A1 (en) * | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
| KR101099206B1 (ko) * | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| WO2006120104A1 (en) * | 2005-04-11 | 2006-11-16 | Probiodrug Ag | Inhibitors of prolyl endopeptidase |
| ATE523788T1 (de) * | 2006-06-08 | 2011-09-15 | Fu Berlin | ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN |
| JP2010504088A (ja) * | 2006-09-21 | 2010-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼに関連した新規遺伝子 |
| WO2008087197A1 (en) * | 2007-01-19 | 2008-07-24 | Probiodrug Ag | In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders |
-
2009
- 2009-07-31 JP JP2011520526A patent/JP5677297B2/ja active Active
- 2009-07-31 KR KR1020117002132A patent/KR101682728B1/ko active Active
- 2009-07-31 CN CN201410221835.XA patent/CN103983787A/zh active Pending
- 2009-07-31 CN CN200980130500.4A patent/CN102112880B/zh active Active
- 2009-07-31 BR BRPI0916601-7A patent/BRPI0916601B1/pt active IP Right Grant
- 2009-07-31 AU AU2009275869A patent/AU2009275869B2/en active Active
- 2009-07-31 WO PCT/EP2009/059951 patent/WO2010012828A2/en not_active Ceased
- 2009-07-31 MX MX2011001093A patent/MX2011001093A/es active IP Right Grant
- 2009-07-31 NZ NZ590658A patent/NZ590658A/en unknown
- 2009-07-31 EA EA201100253A patent/EA025107B1/ru not_active IP Right Cessation
- 2009-07-31 US US12/533,099 patent/US20100028918A1/en not_active Abandoned
- 2009-07-31 CA CA2731933A patent/CA2731933A1/en not_active Abandoned
- 2009-07-31 EP EP09781358.8A patent/EP2329274B1/en active Active
- 2009-07-31 SG SG2013056478A patent/SG193148A1/en unknown
-
2010
- 2010-12-26 IL IL210266A patent/IL210266A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00177A patent/ZA201100177B/en unknown
-
2015
- 2015-03-12 US US14/645,821 patent/US20150247180A1/en not_active Abandoned
-
2016
- 2016-12-14 US US15/378,328 patent/US20170097365A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150247180A1 (en) | 2015-09-03 |
| BRPI0916601B1 (pt) | 2021-05-25 |
| SG193148A1 (en) | 2013-09-30 |
| JP2011529571A (ja) | 2011-12-08 |
| NZ590658A (en) | 2012-07-27 |
| HK1155813A1 (en) | 2012-05-25 |
| ZA201100177B (en) | 2012-02-29 |
| IL210266A0 (en) | 2011-03-31 |
| US20170097365A1 (en) | 2017-04-06 |
| CN103983787A (zh) | 2014-08-13 |
| IL210266A (en) | 2016-04-21 |
| EP2329274A2 (en) | 2011-06-08 |
| KR20110049781A (ko) | 2011-05-12 |
| JP5677297B2 (ja) | 2015-02-25 |
| CA2731933A1 (en) | 2010-02-04 |
| US20100028918A1 (en) | 2010-02-04 |
| KR101682728B1 (ko) | 2016-12-05 |
| EA025107B1 (ru) | 2016-11-30 |
| CN102112880A (zh) | 2011-06-29 |
| WO2010012828A3 (en) | 2010-05-06 |
| WO2010012828A2 (en) | 2010-02-04 |
| EA201100253A1 (ru) | 2011-10-31 |
| EP2329274B1 (en) | 2015-12-02 |
| CN102112880B (zh) | 2014-06-25 |
| BRPI0916601A2 (pt) | 2015-11-10 |
| AU2009275869A1 (en) | 2010-02-04 |
| AU2009275869B2 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pera et al. | Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease | |
| US20170097365A1 (en) | Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases | |
| AU2007357025B2 (en) | High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest | |
| Harada et al. | Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains | |
| EP2504356A1 (en) | Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment | |
| CN102549438B (zh) | Fkbp52-tau相互作用作为新颖治疗靶点用于治疗涉及tau机能失调的神经障碍 | |
| CN102947705A (zh) | 通过确定焦谷氨酸修饰的mcp-1诊断炎性疾病的方法和谷氨酰胺酰基环化酶抑制剂的筛选方法 | |
| El Mouedden et al. | Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides | |
| WO2008031190A1 (en) | Alpha-1-antitrypsin as a diagnostic/prognostic indicator for neurodegenerative diseases | |
| JP2012510614A (ja) | オピオルフィン等の塩基性プロリンリッチ涙液遺伝子産物のバイオマーカーとしての使用 | |
| EP2653872B1 (en) | Biomarker for amyloid-beta -related neurological disorders | |
| US20170030929A1 (en) | Diagnosis of chronic kidney disease by quantitative analysis of post-translational modifications of plasma proteins | |
| HK1155813B (en) | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases | |
| HK1197762A (en) | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases | |
| Magini et al. | Fibroblasts from PS1 mutated pre-symptomatic subjects and Alzheimer's disease patients share a unique protein levels profile | |
| JP2014070037A (ja) | アルツハイマー病の診断薬および診断方法 | |
| Foulds | A Study of α-Synuclein, Parkin and TDP-43; Proteins Implicated in Neurodegenerative Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |